Month: July 2021

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, today announced that Sam Whiting, M.D., Ph.D., chief medical officer, will participate in a webcast panel titled “Developing Therapies for the Next Immuno-Oncology Targets” at the William Blair 2021 Biotech Focus Conference on Wednesday, July 14, 2021 at 2:10 p.m. ET. To access the live or archived recording of the discussion, please visit the investor section of the Tempest website at https://ir.tempesttx.com. About Tempest Therapeutics Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the...

CNOOC Petroleum Europe Limited has exercised two of the three 30-day options available to them, to extend the Safe Boreas at the Buzzard platform complex in the UK sector of the North Sea until end-September 2021. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to www.prosafe.com 9 July 2021Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig Harry Christiansen, Deputy CEO and CFOPhone: +47 51 64 25 17 / +47 478 07 813 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Steven Parry to Retire from DIRTT Board of Directors in May 2022 CALGARY, Alberta, July 09, 2021 (GLOBE NEWSWIRE) — DIRTT Environmental Solutions Ltd. (“DIRTT”) (TSX: DRT, NASDAQ: DRTT) an interior construction company that uses proprietary software to design, manufacture and install fully customizable environments, announced today that the Board of Directors has unanimously appointed Todd Lillibridge as Chair of the Board of DIRTT, succeeding Steven Parry who plans to retire from the Board next May in connection with the Company’s 2022 annual meeting of shareholders. Following the 2022 annual meeting, the DIRTT Board is anticipated to be comprised of seven directors, including the Board Chair. As part of these changes, director Diana Rhoten has succeeded Todd Lillibridge as Chair of the Company’s Compensation Committee. Steven...

Series  RIKB 24 0415Settlement Date  07/14/2021Total Amount Allocated (MM)  5,470All Bids Awarded At (Price / Yield)  99.339 / 2.750Total Number of Bids Received  16Total Amount of All Bids Received (MM)  5,970Total Number of Successful Bids  12Number of Bids Allocated in Full  12Lowest Price / Highest Yield Allocated  99.339 / 2.750Highest Price / Lowest Yield Allocated  99.455 / 2.710Lowest Price / Highest Yield Allocated in Full  99.339 / 2.750Weighted Average of Successful Bids (Price/Yield)  99.389 / 2.730Best Bid (Price / Yield)  99.455 / 2.710Worst Bid (Price / Yield)  99.310 / 2.760Weighted Average of All Bids Received (Price / Yield)  99.383 / 2.730Percentage Partial Allocation (Approximate)  100.00 %Bid to Cover Ratio  1.09

Subjects will be exposed under controlled clinical facilities and medical monitoring to A/Perth/16/2009 (H3N2) or human rhinovirus (hRV-16) to gauge Ampligen’s effectiveness against those, and potentially other viruses OCALA, Fla., July 09, 2021 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has signed a contract to sponsor a Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal antiviral therapy using a human Rhinovirus hRV (common cold virus) and Influenza. This antiviral study will be conducted by hVIVO, a subsidiary of Open Orphan plc, a rapidly growing specialist pharmaceutical services clinical research organization and world leader in vaccine and antiviral testing using human challenge clinical trials. The trial is expected to commence in Q4...

Real-World Claims Data Presented at Annual European Association of Urology Congress Reveal Overall Complication Rates are Lowest after Treatment with the UroLift System WAYNE, Pa., July 09, 2021 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE:TFX) today announced that the largest U.S. healthcare claims and utilization analysis for benign prostatic hyperplasia (BPH) surgical and minimally invasive procedures reveals that overall complication rates are lowest after treatment with the UroLift® System. The research study titled “Analysis of Real-World Healthcare Data of Outcomes of Interventional Procedures in BPH”, which was sponsored by Teleflex, was presented by Dr. Steven Kaplan of Mount Sinai today at the 36th Annual European Association of Urology (EAU) Congress. Dr. Daniel Rukstalis+ of Prisma USC Division of Urology was a co-author...

MORF-057 well tolerated across all phase 1 cohorts Dose-dependent α4β7 receptor occupancy (RO) observed with receptor saturation at 100 mg dose Biomarker changes including lymphocyte subset migration and CCR9 transcript levels provide early proof of biology Conference call today at 8:00 AM ET WALTHAM, Mass., July 09, 2021 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced positive results from its full phase 1 clinical trial for MORF-057, an oral small molecule inhibitor of the α4β7 integrin in development for the treatment of inflammatory bowel disease (IBD). The data were shared today in an ePoster presentation at the Congress of European Crohn’s and Colitis Organisation (ECCO)...

PRESS RELEASE  July 9, 2021  HALF-YEARLY ACHIEVEMENT REPORT ON KERING SHAREQUOTATIONS LIQUIDITY MANDATE AND SIGNING OF A CONTRACT AMENDMENT CHANGING THE RESOURCES ALLOCATED TO THE LIQUIDITY ACCOUNT Pursuant to the liquidity mandate granted by Kering to Rothschild Martin Maurel on February 13, 2019, the following assets appeared on the liquidity account as of June 30, 2021:•        0 Share•        €50,212,359.00  As a reminder, the following assets appeared on the liquidity account as of December 31, 2020:•        0 Share•        €50,187,988.00 In addition, Kering and Rothschild Martin Maurel signed an amendment to the liquidity contract that came into effect on July 1st, 2021. This amendment provides a reduction of €25 million in the resources allocated to the liquidity account. Therefore, on July 1st, the following assets appeared...

Monthly declaration of the total number of shares and voting rights composing the company’s capital (at June 30th, 2021)    This declaration is established in accordance with Article L.233-8 II of the French Code de Commerce and of Article 223-11 of the Règlement Général of the Autorité des marchés financiers (AMF). Date: June 30th, 2021 Total number of shares composing the capital: 37,646,645 Total number of voting rights, gross (1): 37,871,452 Total number of voting rights, net (2): 37,848,955         (1) In accordance with the second paragraph of article 223-11 of the Règlement Général of the AMF, the gross total of voting rights is based on the total number of shares composing the company’s capital which have voting rights, including shares deprived of their voting rights (2) The net total of voting rights is equal to the gross...